1 insider bought €443k of shares over the last 90 days, the latest by 인콘, filed 04 Sept 2026.
Humasis Co. Ltd.: what insiders have been doing
This page follows insider dealings at Humasis Co. Ltd. as filed with DART (FSS), a company from the Health Care sector. The last twelve months, up to 23 October 2026, brought 18 filings signed by 3 insiders.
The record shows 12 purchases on the open market worth €3.0M, made by 2 insiders, against 3 sales by 2 insiders. The totals exclude 11 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €887k, bought by 아티스트 and made public on 3 April 2026 (2.3% of market cap). Those buying include 1 major shareholder.
The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 4 September 2026, 65 days ago. The median gap between a trade and its publication by DART (FSS) is 7 days. That lag is the time during which only the insider knows about the trade.
Compared with its exchange (2,650 companies, median 7 filings), a count of 18 filings is above the norm. Over the whole record (from 2021), the tally stands at 16 purchases and 7 sales.
In the same sector, recent insider purchases at Dynavox Group AB and EssilorLuxottica also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -10.1%Entry ₩3,455 · Close at T+90 ₩3,105
- -42.0%Entry ₩4,215 · Close 23 Oct 2026 ₩2,445
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 87,642 sharesShareKRXDART:20260904000036Canonical exit: 3 Dec 2026 (T+90)
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 147,542 sharesShareKRXDART:20260814002478Canonical exit: 12 Nov 2026 (T+90)
- Other0DART
- ●Executives0DART
- 28,251 sharesKRXDART:20260605000488Canonical exit: 3 Sept 2026 (T+90)
- 28,251 sharesShareKRXDART:20260605000496Canonical exit: 3 Sept 2026 (T+90)
- 144,585 shares@ ₩4,038.37610.86% mcap27.5% of flowShareKRXDART:20260529001867Canonical exit: 25 Aug 2026 (T+90)
- 144,585 sharesKRXDART:20260529001850Canonical exit: 20 Aug 2026 (T+90)
- 371,934 sharesKRXDART:20260522000540Canonical exit: 13 Aug 2026 (T+90)
- 371,934 sharesShareKRXDART:20260522000544Canonical exit: 20 Aug 2026 (T+90)
- 381,422 shares@ ₩4,024.63752.27% mcap72.5% of flowShareKRXDART:20260515002044Canonical exit: 11 Aug 2026 (T+90)
- 381,422 shares2.26% mcap49.6% of flowKRXDART:20260515001992Canonical exit: 11 Aug 2026 (T+90)
- 3,403,634 sharesShareKRXDART:20260423000548
- 5,367,503 sharesShareKRXDART:20260423000541
- 15,355,570 sharesKRXDART:20260423000535
- ShareKRXDART:20260409002121
25 of 59 declarations
About Humasis Co. Ltd.
Humasis is a company specializing in the health and pharmaceutical sector, listed on the XKRX market. It focuses on the development of medical diagnostics and innovative health solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
